TEL AVIV, Israel--(BUSINESS WIRE)-- ETView (TASE: ETVW.TA - News) today announced that the company has successfully completed a Technical File submission for review by Medical Device Certification GmbH (“MDC”). The Technical File review initiates the Conformité Européenne, or “European Conformity” (“CE”) registration process. Following award of CE clearance, The Company expects to begin distribution of the Viva™ EB Line of Endobronchial Blockers in countries requiring CE registration of medical devices. Feedback from MDC is anticipated during the next quarter. Additional pre-market regulatory filings in Europe and Asia are anticipated during 2012.
About the Viva™ EB Endobronchial Blocker
Viva™ EB consists of a sterile, single-use, pre-angulated, balloon tipped catheter which is guided under video imaging to a selected bronchial segment to affect balloon blockage of the distal airway. Air is subsequently evacuated through a dedicated channel, deflating the selected lung and establishing lung isolation. Viva™ EB is employed with an endotracheal tube when used in combination with a fiberoptic bronchoscope to blockade the right or left lung for thoracic surgical procedures requiring lung isolation. Viva™ EB is compatible with ETView’s patented VivaSight™ SL, a single-use disposable single lumen ventilation tube with an integrated continuous high resolution video imaging system for use in lung isolation procedures. VivaSight™ SL has received FDA and CE clearance for commercial distribution.. Lung isolation is employed to provide one-lung ventilation in patients undergoing thoracic, cardiac, vascular or esophageal surgeries.1 It is estimated that over 1.9 million lung isolation procedures are conducted world-wide annually2, accounting for over $250MM in single-use medical disposables3.
“We are excited to have reached this milestone,” stated Bill Edelman, CEO. He continued, “Viva™ EB will be available to the European thoracic surgical community following MDC concurrence with our CE registration application. We anticipate significant clinical interest for the combined VivaSight SL/Viva™ EB products when Viva™ EB is cleared for commercial distribution.”
On February 5, 2012, ETView announced that the company filed a Pre-Marketing Notification Application (510(k)) with the FDA for the Viva™ EB Line of Endobronchial Blockers.
During February 2012, ETView announced distribution agreements with NeuroMed Ltd. (NeuroMed) a surgical products sales and distribution company based in St. Petersburg, Russia, and State of the Art (SOTA) Medical Products, Inc., a specialty surgical products sales and distribution company, based in Cedar Grove, New Jersey.
On December 12, 2011, ETView announced that the company filed a Pre-Marketing Notification Application (510(k)) with the FDA for the VivaSight™ DL Airway Management System. VivaSight™-DL4 is a proprietary, single-use disposable medical device, consisting of a dual lumen airway ventilation tube with an integrated continuous high resolution video airway imaging system permitting airway control and lung isolation during certain surgical procedures.
About the CE Mark
The CE mark (Conformité Européenne, meaning “European Conformity”5, formerly EC mark6) is a mandatory conformity mark for medical devices placed on the market in the European Economic Area (EEA). With the CE marking on a medical device, the manufacturer ensures that the product conforms with the essential requirements of the applicable EC medical device directives.7
About ETView Medical, Ltd.
ETView Medical Ltd. (TASE: ETVW.TA - News) has ETView has pioneered development of the VivaSight™ platform (previously known as TVT™), combining an airway ventilation tube with integrated continuous high resolution airway imaging for patient airway control and lung isolation capability (eliminating the need for fiberoptic bronchoscope8 imaging during these procedures).
ETView’s patented VivaSight™ SL, a single-use disposable medical device, consisting of a single lumen ventilation tube with an integrated continuous high resolution video imaging system is currently sold in Europe, Israel, and the US to overcome current limitations and associated adverse surgical events during lung isolation surgeries9. Visit www.etview.com for additional information.
Forward Looking Statement
The Company estimations in this press release, including those estimations regarding the Company’s predicted scope of business, constitute forward-looking statements, as such term is defined under the Israeli Securities Law (5728-1968), and there is no certainty that such estimations shall materialize. The Company’s estimations are based on business assumptions, prior experience, and professional data. Due to various factors, foreseen and unforeseen, including, but not limited to, changes in market trends, competition, global or local economic conditions, and amendments of regulation, such estimations may not materialize in whole or in part, or materialize in a substantially different manner than anticipated by the Company.
1 Principles and Practices of Anesthesia for Thoracic Surgery P. Singer (ed.) 2011
2 National Health Statistics Reports Number 29, October 26, 2010
3 Company estimates on file
4 Patent Pending
5http://ec.europa.eu/enterprise/faq/index_en.htm#09012624859cd715
6http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31993L0068:en:HTML
7http://ec.europa.eu/enterprise/policies/single-market-goods/cemarking/faq/index_en.htm
8Minerva Anestesiol 2009;75(Suppl 1):1-4.
9 Anesthesiology 2006;105:471–7.
Contact:
ETView Medical, Ltd
Bill Edelman, CEO
Worldwide: +1 567 248 4821
In Israel: +972 72 260 7060
bill.edelman@etview.com
